Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614781 | 0.87 | PKM (0.37) | AKR1B1ALDH1A1CNR1GPR55SCN9A | |
| SCHEMBL16812350 | 0.81 | OPRL1 (0.48) | OPRL1 | |
| SCHEMBL7611042 | 0.78 | ALDH1A1 (0.56) | ALDH1A1SCN9ASMN1; SMN2TP53 | |
| SCHEMBL7614600 | 0.77 | L3MBTL1 (0.54) | ALDH1A1LMNAGAAL3MBTL1 | |
| SCHEMBL7619547 | 0.76 | PKM (0.37) | AKR1B1ALDH1A1CNR1GPR55LMNA | |
| SCHEMBL7619542 | 0.74 | CNR1 (0.35) | AKR1B1ALDH1A1CNR1GPR55LMNA | |
| SCHEMBL1975222 | 0.71 | PRKAG1 (0.42) | ALDH1A1SCN9ALMNAOPRL1GAA | |
| SCHEMBL12555000 | 0.71 | PRKAG1 (0.42) | ALDH1A1SCN9ALMNAOPRL1GAA | |
| SCHEMBL16477271 | 0.71 | PRKAG1 (0.42) | ALDH1A1SCN9ALMNAOPRL1GAA | |
| SCHEMBL7612122 | 0.69 | TP53 (0.49) | AKR1B1ALDH1A1LMNASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0685463-B1 | INDOLIN-2-ONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-6207836-B1 | Indolin-2-one derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6127544-A | 1-SUBSTITUTED-3-UREIDO-INDOLIN-2-ONES WHICH EXHIBIT SELECTIVE ANTAGONISM AGAINST GASTRIN RECEPTORS WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO CCK-A RECEPTOR ANTAGONISM; SUCH AS FOR TREATMENT OF PEPTIC ULCERS, GASTRITIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-10-03 | — | — | US | disclosed |
| US-6114536-A | ANTAGONISM AGAINST GASTRIN RECEPTORS WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO CCK-A RECEPTOR ANTAGONISM AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES OF DIGESTIVE ORGANS, SUCH AS PEPTIC ULCER, GASTRITIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-09-05 | — | — | US | disclosed |
| US-6031111-A | Indolin-2-one derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-02-29 | — | — | US | disclosed |
| US-5952511-A | EXHIBITS SELECTIVE ANTAGONISM AGAINST GASTRIN RECEPTOR WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO GASTRIN RECEPTOR ANTAGONISM AND USEFUL FOR TREATING PEPTIC ULCER, GASTRITIS, REFLUX ESOPHAGITIS AND ZOLLINGER-ELLISON SYNDROME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0685463-A1 | INDOLIN-2-ONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1995-12-06 | — | — | EP | disclosed |